Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp25583_8k.htm |
|
Exhibit 99.01
|
|
|
Press Release
|
 |
|
www.shire.com
|
|
Director/PDMR Shareholding
August 2, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the following dealings by Persons Discharging Managerial Responsibility in Shire plc ordinary shares of 5p (“Shares”) and American Depository Shares (“ADSs”). One ADS is equal to three Shares.
Exercise of Stock Appreciation Rights (“SAR Award”)
The Company was notified on August 2, 2011 of the exercise of the following SAR Awards which were granted under Part A of the Shire Portfolio Share Plan.
|
Type of security
|
Number of Shares/ADSs exercised
|
Exercise price
|
Number of Shares/ADSs released
|
Number of Shares/ADSs
sold
|
Sale price
|
|
|
Graham Hetherington1
|
Shares
|
88,000
|
£8.675
|
51,174
|
51,174
|
£20.233
|
|
Angus Russell²
|
Shares
|
74,800
|
£9.97
|
39,522
|
39,522
|
£21.140
|
|
Matthew Emmens3
|
ADSs
|
78,8254
|
$64.10
|
29,438
|
29,438
|
$102.145
|
|
ADSs
|
30,9105
|
$58.51
|
13,232
|
13,232
|
$102.145
|
1 The SAR Award granted in 2008 to Mr Hetherington was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on August 2, 2011.
² The SAR Award granted in 2008 to Mr Russell was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on August 1, 2011.
3 The SAR Awards, which were exercised on August 1, 2011, were granted in 2007 and 2008 to Mr Emmens, whilst he held the position of Chief Executive Officer of the Company.
4 The SAR Award granted in 2007 was subject to performance criteria measured over the performance period 2007 to 2009. Based on the performance criteria, 84% of the SAR Award vested.
5 The SAR Award granted in 2008 was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested.
Exercise of Share Options
The Company was notified on August 2, 2011, of the exercise on August 1, 2011, of the following option which was granted to Tatjana May in 2004 under the 2000 Executive Share Option Scheme. Ms May chose to use a net settled cashless exercise facility run by the Company.
|
Number of Shares granted
|
Exercise price
|
Number of Shares received
|
Number of Shares sold
|
Sale price
|
|
|
Tatjana May
|
128,755
|
£5.26
|
97,033
|
97,033
|
£21.238
|
Release of ADSs
In addition, on August 2, 2011, the Company was notified of the release to Matthew Emmens on August 1, 2011, of the ADSs awarded in 2008 under the Executive Annual Incentive Plan. This award was in respect of performance in that year whilst Mr Emmens held the position of Chief Executive Officer of the Company.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
|
Name of Director
|
Type of Security
|
Number of ADSs released
|
Number of ADSs sold to satisfy tax liabilities
|
Sale price
|
|
Matthew Emmens
|
ADSs
|
6,471
|
2,511
|
$102.507
|
Resulting Interests
After the above transactions, Angus Russell, Matthew Emmens, Graham Hetherington and Tatjana May hold the following interests.
|
Type of security
|
Number of Shares/ADSs
|
Options
|
SAR Awards
|
PSA Awards
|
Restricted Shares/ADSs
|
|
|
Matthew Emmens
|
ADSs
|
50,429
|
-
|
-
|
-
|
-
|
|
Shares
|
92,874
|
-
|
-
|
-
|
-
|
|
|
Angus Russell
|
ADSs
|
-
|
-
|
168,742
|
121,292
|
11,415
|
|
Shares
|
131,330
|
-
|
404,301
|
221,685
|
37,814
|
|
|
Graham Hetherington
|
Shares
|
4,000
|
1,240
|
317,687
|
301,833
|
28,080
|
|
Tatjana May
|
Shares
|
86,126
|
151,108
|
138,379
|
78,433
|
25,975
|
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Secretary
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.